Home LiteratureArticle Details
PMID: 3160727 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo.

The Journal of clinical investigation ·Vol. 76 ·No. 1 ·1985-07-00 ·Pages 261-70

Hamilton KK, Fretto LJ, Grierson DS, McKee PA

Abstract

von Willebrand factor (vWF), a multimeric protein that mediates platelet adhesion, circulates in association with the procoagulant Factor VIII (FVIII). In previous reports, plasmin was shown in vitro to inactivate FVIII and cleave the vWF subunit extensively, but to cause only a modest decrease in vWF platelet-agglutinating activity. In the present study, the digestion of vWF multimers by plasmin was analyzed by sodium dodecyl sulfate-agarose gel electrophoresis and radioimmunoblotting. In vitro, plasmin degraded the large vWF multimers to smaller forms that could be distinguished from the small multimers present before digestion only by a slightly increased electrophoretic mobility. These plasmin-cleaved "multimers" were composed of disulfide-linked fragments with no intact vWF subunits. Thus, many plasmin cleavages occur within disulfide loops. The slight increase in mobility of plasmin-digested vWF is in part explained by the early cleavage from the multimers of a 34,000-mol wt peptide, which was purified and partially sequenced. The amino-terminal sequence (33 residues) agrees with the previously reported sequence (15 residues) for the amino terminus of the intact vWF subunit. Analysis of plasmin-digested vWF allowed deduction of a model for the native vWF structure, including the approximate location of the interprotomer disulfide bond(s). To determine whether plasmin would digest vWF in vivo, plasmas from 12 patients and 2 normal volunteers who received intravenous streptokinase (SK) were analyzed. Rather than vWF digestion, a two- to threefold rise in vWF antigen and platelet-agglutinating activity occurred within 2 h after a single SK dose, and the increase was greatest among the largest multimers. In contrast, FVIII clotting activity dropped to 10-20% of pre-SK levels. Thus, although plasmin destroys FVIII, a pharmacologically induced fibrinolytic state is associated with significant release of vWF from endothelial cells, platelets, or some other storage pool.

MeSH Terms
Blood Coagulation Factors/metabolism Factor VIII/metabolism Fibrinolysin/metabolism Humans Macromolecular Substances Molecular Weight Streptokinase/pharmacology Time Factors Trypsin/metabolism von Willebrand Factor/metabolism
Chemicals
Blood Coagulation Factors Macromolecular Substances von Willebrand Factor Factor VIII Streptokinase Trypsin Fibrinolysin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Hamilton K K
Fretto L J
Grierson D S
McKee P A
References (39)
39 references, click to expand
  1. Plasminogen: purification from human plasma by affinity chromatography.
    Science. 1970 Dec 4;170(3962):1095-6 PMID: 5475635
  2. In-vitro and in-vivo studies of a preparation of urokinase.
    Br Med J. 1963 Apr 6;1(5335):909-15 PMID: 13932245
  3. Maturation of the head of bacteriophage T4. I. DNA packaging events.
    J Mol Biol. 1973 Nov 15;80(4):575-99 PMID: 4204102
  4. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.
    Br J Haematol. 1975 May;30(1):81-93 PMID: 1191576
  5. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.
    J Clin Invest. 1976 Apr;57(4):925-37 PMID: 1084890
  6. In vivo and in vitro effects of thrombin and plasmin on human factor VIII (AHF).
    Am J Hematol. 1976;1(4):481-91 PMID: 137671
  7. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein.
    J Biol Chem. 1977 Aug 10;252(15):5538-46 PMID: 301877
  8. Effects of enzymatic degradation on the subunit composition and biologic properties of human factor VIII.
    Blood. 1978 Feb;51(2):281-97 PMID: 145884
  9. Localization of the alpha-chain cross-link acceptor sites of human fibrin.
    J Biol Chem. 1978 Apr 10;253(7):2184-95 PMID: 632262
  10. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.
    J Clin Invest. 1978 Sep;62(3):702-9 PMID: 308512
  11. Plasmin digestion of factor VIII: characterization of the breakdown products with respect to antigenicity and von Willebrand activity.
    Thromb Haemost. 1978 Oct 31;40(2):302-15 PMID: 153594
  12. Binding of human thrombin to cultured human endothelial cells.
    J Biol Chem. 1979 May 25;254(10):4092-5 PMID: 438177
  13. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers.
    Biochim Biophys Acta. 1979 May 23;578(1):164-74 PMID: 454664
  14. Immunologic studies of native and modified human factor VIII/von Willebrand factor.
    Blood. 1979 Aug;54(2):310-21 PMID: 88237
  15. An improvemed assay for von Willebrand factor.
    Am J Clin Pathol. 1979 Dec;72(6):991-5 PMID: 117698
  16. Support of ristocetin-induced platelet aggregation by procoagulant-inactive and plasmin-cleaved forms of human factor VIII/von Willebrand factor.
    Blood. 1980 Jan;55(1):101-8 PMID: 6444272
  17. Localization of factor-VIII-related antigen in human vascular subendothelium.
    Blood. 1980 May;55(5):752-6 PMID: 6244867
  18. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.
    Blood. 1980 Jun;55(6):1056-9 PMID: 6769518
  19. Reactions of thrombin with human factor VIII/von Willebrande factor protein.
    J Biol Chem. 1980 Nov 25;255(22):10606-11 PMID: 6776120
  20. Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins.
    Science. 1981 Mar 27;211(4489):1437-8 PMID: 6162199
  21. A gas-liquid solid phase peptide and protein sequenator.
    J Biol Chem. 1981 Aug 10;256(15):7990-7 PMID: 7263636
  22. Alterations of factor VIII von Willebrand factor in clinical conditions associated with an increase in its plasma concentration.
    Br J Haematol. 1981 Sep;49(1):61-8 PMID: 6791681
  23. Blood coagulation changes during effective thrombolysis using urokinase and heparin.
    Thromb Res. 1982 Jan 1-15;25(1-2):11-21 PMID: 6175040
  24. Association between factor VIII related antigen and plasminogen activator.
    Acta Med Scand. 1982;211(1-2):105-12 PMID: 6803518
  25. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
    Blood. 1982 Jun;59(6):1272-8 PMID: 6805532
  26. Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture.
    Blood. 1982 Aug;60(2):531-4 PMID: 6807373
  27. Thrombin potentiation of factor VIII procoagulant activity: assessment by the two-stage assay.
    Thromb Haemost. 1982 Apr 30;47(2):145-9 PMID: 6213066
  28. Altered factor VIII in acute respiratory failure.
    N Engl J Med. 1982 Oct 28;307(18):1113-9 PMID: 6214713
  29. Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function.
    J Cell Biol. 1982 Nov;95(2 Pt 1):632-40 PMID: 6815213
  30. Localization of factor VIII/von Willebrand factor antigen by immunoelectron microscopy in human endothelial cells using Fab fragments coupled to peroxidase.
    J Histochem Cytochem. 1982 Nov;30(11):1091-6 PMID: 6815260
  31. Isoelectric focusing of human von Willebrand factor in urea-agarose gels.
    Blood. 1983 Feb;61(2):304-10 PMID: 6600402
  32. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.
    Blood. 1984 Feb;63(2):486-9 PMID: 6419799
  33. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (1).
    N Engl J Med. 1984 Sep 13;311(11):710-7 PMID: 6382006
  34. Thrombin-induced release of von Willebrand factor from endothelial cells is mediated by phospholipid methylation. Prostacyclin synthesis is independent of phospholipid methylation.
    J Biol Chem. 1984 Nov 10;259(21):13329-33 PMID: 6436246
  35. Platelet interaction with rabbit subendothelium in von Willebrand's disease: altered thrombus formation distinct from defective platelet adhesion.
    J Clin Invest. 1984 Nov;74(5):1730-41 PMID: 6334102
  36. Structure-function relationships of human factor VIII complex studied by thioredoxin dependent disulfide reduction.
    Thromb Res. 1984 Sep 15;35(6):637-51 PMID: 6438823
  37. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  38. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure.
    J Lab Clin Med. 1953 Apr;41(4):637-47 PMID: 13045017
  39. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.
    Br J Haematol. 1971 Jul;21(1):1-20 PMID: 5559480
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1985-07-00
Pages
261-70
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC423761
Subset
IM
Grants
NHLBI NIH HHS · HL-07101 · United States
NHLBI NIH HHS · HL-15615 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com